NO20085257L - Purinonderivater som HM74a-agonister - Google Patents

Purinonderivater som HM74a-agonister

Info

Publication number
NO20085257L
NO20085257L NO20085257A NO20085257A NO20085257L NO 20085257 L NO20085257 L NO 20085257L NO 20085257 A NO20085257 A NO 20085257A NO 20085257 A NO20085257 A NO 20085257A NO 20085257 L NO20085257 L NO 20085257L
Authority
NO
Norway
Prior art keywords
purinone derivatives
hm74a agonists
agonists
purinone
derivatives
Prior art date
Application number
NO20085257A
Other languages
English (en)
Inventor
Brian Metcalf
Anlai Wang
Chu-Biao Xue
Changsheng Zheng
Ganfeng Cao
Michael Xia
Hai Fen Ye
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of NO20085257L publication Critical patent/NO20085257L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Foreliggende oppfinnelse angår purinonderivater som er agonister av HM74areseptoren. Videre tilveiebringes det preparater og metoder for anvendelse av forbindelsene her og deres farmasøytisk akseptable salter for behandling av sykdom.
NO20085257A 2006-06-23 2008-12-16 Purinonderivater som HM74a-agonister NO20085257L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81595506P 2006-06-23 2006-06-23
US92281807P 2007-04-11 2007-04-11
PCT/US2007/071891 WO2007150025A2 (en) 2006-06-23 2007-06-22 Purinone derivatives as hm74a agonists

Publications (1)

Publication Number Publication Date
NO20085257L true NO20085257L (no) 2009-01-19

Family

ID=38721463

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085257A NO20085257L (no) 2006-06-23 2008-12-16 Purinonderivater som HM74a-agonister

Country Status (14)

Country Link
US (4) US7511050B2 (no)
EP (1) EP2044074A2 (no)
JP (1) JP5584466B2 (no)
KR (1) KR20090025261A (no)
CN (1) CN101466714B (no)
AR (1) AR061625A1 (no)
AU (1) AU2007260851B2 (no)
BR (1) BRPI0713619A2 (no)
CA (1) CA2656039A1 (no)
IL (1) IL195904A0 (no)
MX (1) MX2009000170A (no)
NO (1) NO20085257L (no)
TW (1) TWI423977B (no)
WO (1) WO2007150025A2 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
TWI423977B (zh) 2006-06-23 2014-01-21 Incyte Corp 作為ｈｍ７４ａ同效劑之嘌呤酮衍生物（一）
JP5274455B2 (ja) * 2006-06-23 2013-08-28 インサイト コーポレイション Ｈｍ７４ａアゴニストとしてのプリノン誘導体
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR101799429B1 (ko) * 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA3032229A1 (en) 2016-07-27 2018-02-01 Hartis-Pharma Sa Therapeutic combinations to treat red blood cell disorders
AR112457A1 (es) * 2017-08-02 2019-10-30 Lilly Co Eli Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona
MX2020004981A (es) 2017-10-27 2020-08-24 Bayer Ag Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
US20190292188A1 (en) 2018-02-27 2019-09-26 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
MX2020012376A (es) 2018-05-18 2021-03-09 Incyte Corp Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
AU2019297361A1 (en) 2018-07-05 2021-02-25 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE863525A (fr) 1977-02-14 1978-07-31 Bristol Myers Co Heterocyclopyrimidines
CA1095906A (en) * 1977-02-14 1981-02-17 Davis L. Temple, Jr. Heterocyclopyrimidines, compositions and therapeutic process
US4404380A (en) * 1977-02-14 1983-09-13 Mead Johnson & Company Triazolopyrimidines
EP0425541A1 (en) * 1988-07-21 1991-05-08 The Upjohn Company Pyrazolo-azolo-pyrimidine-diones
DE69029303T2 (de) * 1989-09-14 1997-05-28 Kyowa Hakko Kogyo Kk 5-Triazolo(3,4-i)purinderivate
JPH083168A (ja) * 1994-06-15 1996-01-09 Yamasa Shoyu Co Ltd ４−メチル−９Ｈ−イミダゾ［１，２−ａ］プリン−９−オン類
JP3204879B2 (ja) 1995-08-04 2001-09-04 オリエンタル酵母工業株式会社 パン用酵母の包装紙
EP0879183A1 (fr) 1996-07-18 1998-11-25 Montania Bouchon avec recipient auxiliaire et procede de realisation
DE19629378A1 (de) 1996-07-20 1998-01-29 Boehringer Ingelheim Kg Neue Triazolopurine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU7966098A (en) 1997-06-12 1998-12-30 Smithkline Beecham Corporation Hm74a receptor
EP1092435B1 (en) 1998-07-02 2007-04-04 Kyowa Hakko Kogyo Co., Ltd. Remedies for diabetes
AU2223501A (en) 1999-12-24 2001-07-09 Kyowa Hakko Kogyo Co. Ltd. Fused purine derivatives
AU1560802A (en) 2000-06-28 2002-01-08 Smithkline Beecham Plc Wet milling process
BR0115833A (pt) 2000-12-01 2003-10-28 Biogen Inc Derivados condensados de purina como antagonistas de receptores de adenosina a1
WO2002084298A2 (en) 2001-04-11 2002-10-24 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
UA80258C2 (en) 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
US7465548B2 (en) 2003-02-17 2008-12-16 Bayer Healthcare Ag Methods of screening for potential therapeutics for diseases associated with G-protein coupled receptor HM74a
KR101100601B1 (ko) 2004-02-14 2011-12-29 글락소스미스클라인 엘엘씨 신규 화합물
US20050205364A1 (en) 2004-03-12 2005-09-22 Browne Alan L Variable resistance strut assemblies and articles containing the same
US7267695B2 (en) 2004-06-25 2007-09-11 American Prosthetic Components, Inc. Four hole offset alignment device
WO2006021892A2 (en) 2004-08-27 2006-03-02 Endocube S.A.S. Hm74 and hm74a in cuboidal endothelial cells as associated with inflammation
WO2006045565A1 (en) * 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
WO2006045564A1 (en) * 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
GB0516462D0 (en) 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
JP2009504592A (ja) 2005-08-10 2009-02-05 スミスクライン・ビーチャム・コーポレイション 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体
TWI423977B (zh) 2006-06-23 2014-01-21 Incyte Corp 作為ｈｍ７４ａ同效劑之嘌呤酮衍生物（一）
JP5274455B2 (ja) 2006-06-23 2013-08-28 インサイト コーポレイション Ｈｍ７４ａアゴニストとしてのプリノン誘導体

Also Published As

Publication number Publication date
US8039478B2 (en) 2011-10-18
CA2656039A1 (en) 2007-12-27
US20140371216A1 (en) 2014-12-18
AU2007260851A1 (en) 2007-12-27
CN101466714B (zh) 2013-02-06
US20080045554A1 (en) 2008-02-21
EP2044074A2 (en) 2009-04-08
JP5584466B2 (ja) 2014-09-03
BRPI0713619A2 (pt) 2013-01-15
WO2007150025A2 (en) 2007-12-27
US7511050B2 (en) 2009-03-31
KR20090025261A (ko) 2009-03-10
AU2007260851B2 (en) 2013-01-17
US8703783B2 (en) 2014-04-22
US20090286774A1 (en) 2009-11-19
WO2007150025A3 (en) 2008-02-07
TWI423977B (zh) 2014-01-21
CN101466714A (zh) 2009-06-24
AR061625A1 (es) 2008-09-10
JP2009541355A (ja) 2009-11-26
TW200813064A (en) 2008-03-16
IL195904A0 (en) 2009-09-01
MX2009000170A (es) 2009-01-23
US20120035172A1 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
NO20085257L (no) Purinonderivater som HM74a-agonister
NO20085099L (no) Puritonderivativer som HM74A agonister
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
NO20075298L (no) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
NO20083669L (no) 4-aryl-2amino-pyrimidiner eller 4-aryl-2-aminoalkylpyrimidiner som jak-2-modulatorer og fremgangsmater for anvendelse derav
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
NO20082793L (no) Nye tiofenderivater
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
DE602005023197D1 (de) -muscarinrezeptors
TNSN08326A1 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
TW200728307A (en) Novel spirochromanone derivatives
WO2007133802A3 (en) Pharmaceutical formulations of pimavanserin
NO20093146L (no) Amino-pyridinderivater som S1P1/EDG1-reseptoragonister
MA32467B1 (fr) Derives de piperidinyle agonistes de gpcr
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
NO20076648L (no) Novel thiophene derivatives
NO20075113L (no) Proteinkinaseinhibitorer
TW200740814A (en) Compounds
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20084301L (no) Tetrahydronaftalenderivater, fremgangsmate for deres fremstilling og anvendelse derav som anti-inflammatoriske midler
MY149854A (en) Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
TW200801022A (en) Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application